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Abstract
The objective of the research was to increase the efficiency of treatment of patients with chronic heart failure (CHF) and
post-infarction cardiosclerosis by adding potassium and magnesium salts of gluconic acid, eplerenone and rivaroxaban to the
background therapy taking into account the indices of growth differentiation factor 15 (GDF-15), aldosterone and galectin-3.
Materials and methods of the research. Emmunoenzymometric determination of the galectin-3, GDF-15 and aldosterone
levels concentration in blood serum was conducted to achieve the stated objective. 42 patients with CHF and post-infarction
cardiosclerosis after coronary artery stenting in the acute period of myocardial infarction (MI) were examined. The patients
were randomized into four groups according to the peculiarities of treatment. Group I included patients with CHF and
post-infarction cardiosclerosis treated with the background therapy (BT). Group II consisted of patients with CHF who were
treated with BT and addition of potassium and magnesium salts of gluconic acid. Group III included patients with CHF who
were prescribed eplerenone secondary to BT. Group IV consisted of patients who were treated with BT and rivaroxaban.
Results. The proposed treatment regimens were proved to be effective in reduction of GDF-15, aldosterone and galectin-3
indices in 12 months of treatment. Conducted therapy with the use of rivaroxaban secondary to BT led to more intensive
decrease in GDF-15 concentration in comparison with the use of potassium and magnesium salts of gluconic acid or
eplerenone on the background of BT. This index constituted (2110.21±107.4) pg/ml before the treatment in these patients
and significantly decreased to (1286.75±109.6) pg/ml being significantly before the therapy. The performed treatment with
the use of eplerenone secondary to BT was proved to be more effective for normalization of aldosterone and galectin-3
levels in blood serum compared to other studied treatment regimens. The average value of aldosterone changed in the
treatment process by 67.24%. Thus, the average level of this index constituted (139.8±7.63) pg/ml before the treatment and
was equal to (45.8±5.52) pg/ml at the end of the treatment course. The average value of galectin-3 in patients with CHF
and post-infarction cardiosclerosis was noted to be (34.69±1.67) ng/ml before the treatment. It constituted (22.53±0.98)
ng/ml after the end of treatment being significantly lower compared to the value before the treatment. The average value of
this index changed in the course of twelve-month treatment by 35.05%. Lower risk of sudden cardiac arrest (SCA), acute
coronary syndrome (ACS) and stroke was observed in the patients with CHF and post-infarction cardiosclerosis with the use
of rivaroxaban secondary to BT.
Conclusions. Thus, the use of rivaroxaban combination therapy secondary to BT led to more intensive decrease in GDF-15
concentration in comparison with the use of potassium and magnesium salts of gluconic acid or eplerenone. Conducted
therapy with the use of eplerenone on the background of BT was more effective for the normalization of galectin-3 and
aldosterone levels in the blood compared to other studied treatment regimens.
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Problem statement and analysis of the
recent research
The frequency of hospitalization and mortality in case of CHF
and post-infarction cardiosclerosis remains high despite the
advances in modern medicine. In this regard the search for
specific markers becomes more urgent. Their task consists
in early diagnosis, prognosis of CHF course and its compli-
cations, monitoring of treatment efficacy and patients’ risk
stratification [1].
One of the achievements of modern medicine is the dis-
covery of a new biomarker, namely GDF-15 [9] which is a
stress-induced marker, macrophage-inhibitory cytokine-1. It
belongs to super family of proteins of transforming growth
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factor β . It is an inflammatory marker and a marker of haemo-
dynamic load as well as apoptosis and cardiac muscle re-
modeling. GDF-15 prognostic value in various periods of
the disease was shown in several studies where its role in
risk stratification of patients with MI (GUSTO-IV, FRISC-
2, ASSENT-2, AMI) was evaluated [12, 13]. Retrospective
study analyses have shown that high levels of GDF-15 are
associated with increased risk of death and/or repeated AMI
[14]. According to some data, this biomarker is a more ac-
curate marker of CHF with preserved left ventricular (LV)
ejection fraction while natriuretic peptide (NUP) better shows
the course of systolic heart failure [15].The level of GDF-15
correlates with the severity of CHF manifestations and LV
diastolic dysfunction indices [8].
The role of aldosterone in CHF development including
myocardial injury is beyond argument [7]. As a component
of angiotensin aldosterone system, it significantly influences
fluid retention and edema formation, potassium excretion and
sodium retention, remodeling, fibroid heart and vessels scle-
rosis. It acts at the level of cell genome like other steroid
hormones. According to modern concepts, weak inhibition of
aldosterone activity is one of the possible reasons for insuffi-
cient efficacy of standard therapy in the treatment of chronic
heart failure with post-infarction cardiosclerosis [10].
Galectin-3 is also CHF prospective marker which belongs
to the family of β -galactoside-binding proteins and is ex-
pressed by many cells including neutrophils, macrophages,
labrocytes, fibroblasts and osteoblasts. It is normally not
observed in cardiomyocytes [4]. According the study of E.
Grandin galectin-3 is associated with the risk of CHF devel-
opment after AMI. This adds evidence in favor of its use as a
biomarker of adverse LV remodeling [5]. In general, the study
of galectin-3 properties was conducted with the participation
of more than 16 900 patients. This provides an opportunity
to consider this lectin to be the most studied cardiovascular
biomarker after NUP [2]. However, the possibility of its ap-
plication in clinical practice remains unexplained to this day
[6].
The objective of the research was to increase the efficiency
of treatment of patients with chronic heart failure (CHF) and
post-infarction cardiosclerosis by adding potassium and mag-
nesium salts of gluconic acid, eplerenone and rivaroxaban
to the background therapy taking into account the indices of
growth differentiation factor 15 (GDF-15), aldosterone and
galectin-3.
1. Materials and methods of the research
The research was performed at the premises of Ivano-Frankivsk
Regional Clinical Cardiology Dispensary. 42 patients with
CHF and post-infarction cardiosclerosis were examined. All
examined patients were divided into the following groups.
Group I included 9 patients with CHF after past AMI with
conducted stenting who underwent BT (metoprolol succinate
in a dose of 25 mg/day, clopidogrel in a dose of 75 mg/day,
aspirin-cardio in a dose of 75 mg/day, atorvastatin in a dose
of 20 mg/day, enalapril in a dose of 5 mg/day, trimetazidine
in a dose of 70 mg/day, torasemide in a dose of 10 mg/week).
Group II consisted of 12 patients with CHF after past AMI
with conducted stenting who were treated with BT and addi-
tion of potassium and magnesium salts of gluconic acid in a
dose of 360 mg 3 times per day. Group III included 11 patients
with CHF after past MI with the stenting who were prescribed
eplerenone in a dose of 25 mg 2 times a day secondary to BT.
Group IV consisted of 10 patients with CHF after past AMI
with conducted stenting who received the combined treatment
with BT medication together with rivaroxaban in a dose of 2.5
mg 2 times a day.
Emmunoenzymometric determination of the galectin-3,
GDF-15 and aldosterone levels concentration in blood serum
was conducted to achieve the stated objective. GDF-15 level
in blood serum was determined using Human GDF-15/MIC-1
ELISA (“BioVendor”, Czech Republic). Galectin-3 level in
blood serum was determined with the use of BMS279/2TEN,
Human Galectin-3 (Bender MedSystems, Austria). Aldos-
terone concentration was determined using the ELISA kit
(EIA-4128, Aldosterone ELISA) for the direct quantitative
determination in blood serum.
2. Results of the research and their
discussion
The therapy impact on aldosterone and GDF-15 levels in the
patients’ blood was analyzed.
As Table 1 shows, all studied treatment regimens led to a
significant decrease in the average level of aldosterone after
therapy completion. The average aldosterone concentration
was found to be (125.1±6.23) pg/ml before the treatment
and significantly decreased under the influence of BT treat-
ment to (100.7±6.45) pg/ml in the patients of Group I. In
case of adding potassium and magnesium salts of gluconic
acid to BT, the average value of this index in the patients of
Group II constituted (135.3±7.18) pg/ml before the treat-
ment and (105.1±8.44) pg/ml after the therapy (p<0.05).
The application of the therapy with eplerenone in patients
of Group III led to more intensive decrease in aldosterone con-
centration in comparison with other medications (p1-3<0.001,
p2-3<0.001).The average value of this index changed in the
course of treatment by 70.9%.Thus, the average level of this
index constituted (127.4±6.79) pg/ml before the treatment
and was equal to (37.1±4.67) pg/ml at the end of the treatment
course. Aldosterone concentration in Group IV constituted
(131.7±8.53) pg/ml before the treatment and decreased by
25.4% to the level of (98.2±7.84) pg/ml (p<0.01) under the
influence of the treatment.
GDF-15 average value in the patients of Group I was found
to constitute (2069.78±101.8) pg/ml before the treatment
and significantly decreased to the level of (1821.98±104.6)
pg/ml (p¿0.05)under the influence of BT. In case of potas-
sium and magnesium salts of gluconic acid adding to BT,
the average value of this index in the patients of Group II
constituted (2195.08±101.6) pg/ml before the treatment and
Dynamics of Heart Failure Markers in Patients after Past Myocardial Infarction with the Use of Potassium and
Magnesium Salts of Gluconic Acid, Eplerenone and Rivaroxaban — 3/5
Table 1. The therapy impact on GDF-15 and aldosterone levels in patients with CHF after past MI
Group of patients Aldosterone level (pg/ml) GDF-15 level (pg/ml)
Before the treatment After the treatment Before the treatment After the treatment
Group I BT (n=9) 125.1±6.23 100.7±6.45 ∆-19.5
p<0.05 ∆-33,92
2069.78±101.8 1821.98±104.6
∆-11.9 p>0.05
Group II BT + potas-
sium and magnesium
salts of gluconic acid
(n=11)
135.3±7.18 105.1±8.44 ∆-22.3
p<0.05 p1-2>0.05
2195.08±101.6 1845.97±100.9
∆-15.9 p<0.05
p1-2>0.05
Group III BT+
eplerenone (n=12)
127.4±6.79 37.1±4.67 ∆-70.9
p<0.001 p1-3<0.001
p2-3<0.001
2297.64±103.6 1785.65±104.7
∆-22.3 p<0.01
p1-3>0.05 p2-3>0.05
Group IVBT + ri-
varoxaban (n=10)
131.7±8.53 98.2±7.84 ∆-25.4
p<0.01 p1-4>0.05
p2-4>0.05
p3-4<0.001
2365.85±102.7 1464.23±105.8 ∆
-38.1 p<0.001
p1-4<0.05 p2-4<0.05
p3-4<0.05
Note.
p – the probability of difference between average values before and after the treatment;
p1-2 – the probability of difference between average values of Group I and II;
p1-3 – the probability of difference between average values of Group I and III;
p2-3 – the probability of difference between average values of Group II and III;
p2-4 – the probability of difference between average values of Group II and IV;
p3-4 – the probability of difference between average values of Group III and IV.
(1845.97±100.9) pg/ml after the therapy completion which
was significantly lower compared to the same value before
the treatment. The average level of GDF-15 in the patients
of Group III treated with eplerenone secondary to BT was
(2297.64±103.6) pg/ml before the treatment and (1785.65±104.7)
pg/ml (p<0.01) at the end of the treatment course. Thus,
eplerenone was found to be more effective in reduction of this
index concentration than potassium and magnesium salts of
gluconic acid, GDF-15 level changed by 22.3% in the treat-
ment course. Rivaroxaban therapy was determined to result
in more intense decrease in GDF-15 concentration than potas-
sium and magnesium salts of gluconic acid or eplerenone
(p<0.001).
According to Fig. 1, rivaroxaban treatment of group IV
patients secondary to BT during 12 months contributed to a
probable decrease in GDF-15 level to 38.1%. Thus, the av-
erage value of this index constituted (2365.85±102.7) pg/ml
before the treatment and (1464.23±105.8) pg/ml after therapy
completion which was significantly lower in comparison with
the same value before the treatment. It should be noted that
the application of rivaroxaban therapy secondary to BT led
to a more intensive decrease in GDF-15 concentration com-
pared to the application of potassium and magnesium salts of
gluconic acid or eplerenone.
The therapy impact on galectin-3 level in the patients’
blood was analyzed.
According to Fig.2, galectin-3 level was equal to (35.63±1.73)
ng/ml before the treatment in patients treated with BT and
significantly decreased by 18.3% to the level of (29.11±1.26)
Figure 1. The influence of the conducted therapy on
GDF-15 concentration
Note. The probability of difference between average values before
and after the treatment – *p<0.05; **p<0.01; ***p<0.001
ng/ml after the course of treatment. Galectin-3 level in blood
constituted (32.31±1.34) ng/ml before the treatment in the
group of patients who underwent BT with the addition of
potassium and magnesium salts of gluconic acid. It statis-
tically changed after the therapy by 17.3% and constituted
(26.72±1.16) ng/ml (p<0.01). Complex therapy with the use
of eplerenone secondary to BT was the most effective for
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Figure 2. The influence of the conducted therapy on
galectin-3 concentration
Note. The probability of difference between average values before
and after the treatment – *p<0.05; **p<0.01; ***p<0.001
the normalization of galectin-3 in blood in comparison with
other studied treatment regimens. Thus, this index constituted
(37.68±1.53) ng/ml before the treatment in the patients of
Group III and significantly decreased to (21.88±1.46) ng/ml.
The average value of this index was changed in the treatment
course by 41.9%. Galectin-3 level was (33.27±1.12) ng/ml
before treatment and significantly decreased after therapy
completion to (26.77±1.23) ng/ml (p<0.001) in the patients
of Group IV who were treated with BT medication and ri-
varoxaban.
Odds ratio of SCA, ACS and stroke development in pa-
tients with CHF after MI depending on the characteristics of
differentiated therapy were calculated.
Figure 3. The odds of the studied events occurrence in the
patients with CHF after MI under the influence of the
background therapy
Analysis of the odds of the studied events occurrence de-
tected that BT application did not affect the odds of SCA
(OR=0.31; CI=0.08- 1.18) and stroke (OR=0.29 (CI=0.06-
1.35)) development. However, the risk of ACS develop-
ment significantly decreased under BT influence (OR=0.15;
CI=0.035-0.64).
Figure 4. The odds of the studied events occurrence in the
patients with CHF after MI under the influence of the
background therapy and rivaroxaban
At the same time the decrease in odds of not only SCA
(OR=0.12 (CI=0.02-0.87)) but also of ACS (OR=0.17 (CI=0.04-
0.7)) and stroke (OR=0.24; CI= 0.06-1.86) was observed in
the patients of group IV in case of therapy application.
Thus, the higher efficiency of therapy in case of BT and
rivaroxaban combination to prevent the development of cer-
tain complications in the postinfarction period was proved in
comparison with use of BT solely in patients with CHF after
MI.
3. Conclusions
• The use of combination therapy with rivaroxaban sec-
ondary to BT was found to lead to a more intensive
decrease in GDF-15concentration in comparison with
the use of potassium and magnesium salts of gluconic
acid or eplerenone.
• Conducted therapy with the use of eplerenone sec-
ondary to BT was more effective for the normaliza-
tion of galectin-3 and aldosterone levels in the blood
compared to other studied treatment regimens.
• Lower risk of SCA, ACS and stroke was observed in
patients with CHF and post-infarction cardiosclerosis
after stenting in the acute period of myocardial infarc-
tion in case of rivaroxaban use secondary to BT.
4. Prospects for further research
Prospects for further research involve further studies aimed at
the monitoring of the conducted treatment efficacy.
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